Results: Five trials (a total of 553 patients) met the inclusion criteria. Compared with
interrupting warfarin therapy (either partial or complete), perioperative continuation
of warfarin with patients’ usual dose was not associated with an increased risk for clinically
significant nonmajor bleeding (relative risk [RR], 0.71; 95% confidence interval
[CI]: 0.39–1.28; p = 0.65; I2 = 0%) or an increased risk for minor bleeding (RR, 1.19; 95%
CI: 0.90–1.58; p = 0.22; I2 = 0%).